{"id":"sorafenib-with-low-dose-fp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Myelosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sorafenib inhibits multiple receptor tyrosine kinases (RAF, VEGFR, PDGFR) involved in tumor growth and blood vessel formation. The addition of low-dose fluoropyrimidine chemotherapy provides complementary cytotoxic activity. This combination approach aims to improve efficacy over sorafenib monotherapy in hepatocellular carcinoma and potentially other solid tumors.","oneSentence":"Sorafenib is a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, combined with low-dose fluoropyrimidine (FP) chemotherapy to enhance anti-tumor effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:35:23.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (Phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT01214343","phase":"PHASE3","title":"Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC","status":"UNKNOWN","sponsor":"Ministry of Health, Labour and Welfare, Japan","startDate":"2010-10","conditions":"Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular","enrollment":190},{"nctId":"NCT00933816","phase":"PHASE1, PHASE2","title":"Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy","status":"COMPLETED","sponsor":"Kindai University","startDate":"2009-07","conditions":"Hepatocellular Carcinoma","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexavar","Low-dose FP"],"phase":"phase_3","status":"active","brandName":"Sorafenib with Low-dose FP","genericName":"Sorafenib with Low-dose FP","companyName":"Ministry of Health, Labour and Welfare, Japan","companyId":"ministry-of-health-labour-and-welfare-japan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib is a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, combined with low-dose fluoropyrimidine (FP) chemotherapy to enhance anti-tumor effects. Used for Hepatocellular carcinoma (Phase 3 investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}